DOD Biotech PCL - Stock

DOD Biotech PCL P/E 2024

DOD Biotech PCL P/E

263.23

Ticker

DOD.BK

ISIN

TH8569010003

As of Jun 15, 2024, DOD Biotech PCL's P/E ratio was 263.23, a -3,882.04% change from the -6.96 P/E ratio recorded in the previous year.

The DOD Biotech PCL P/E history

DOD Biotech PCL Aktienanalyse

What does DOD Biotech PCL do?

DOD Biotech PCL is a Thai biotechnology company specializing in the production of pharmaceuticals, diagnostics, and research products. Established in 2004, the company has become one of the most reputable biotechnology companies in Thailand. Its business model is based on the development and manufacturing of products used in medicine, veterinary medicine, and research. DOD Biotech PLC focuses on continually evolving and adapting its products to meet customer needs. Its main areas of focus are the production of pharmaceuticals, particularly anti-cancer drugs, diabetes medications, cardiovascular medications, and infection treatments. Additionally, the company manufactures diagnostics for disease early detection and precise diagnosis. It also offers a variety of products for research purposes. DOD Biotech PCL has partnerships with several companies in other countries, particularly in Asia and Europe. Its largest partner is the Indian company Sun Pharma, with which it has had a successful collaboration for many years. The company is known for its high-quality standards and is certified to ISO 9001:2015 and follows the Good Manufacturing Practices (GMP) required by the Thai FDA. DOD Biotech PCL has received international recognition, including the Frost & Sullivan Thailand Excellence Award and being recognized as a top 30 company in Thailand in 2020. Over the years, the company has built a loyal customer base that appreciates its high-quality products and excellent customer service. It has a strong online presence to better reach and serve its customers. In summary, DOD Biotech PCL is a leading biotechnology company in Thailand with a wide range of pharmaceuticals, diagnostics, and research products. It has earned an excellent reputation for its high-quality standards and top-notch customer service. With its strong online presence and partnerships with other companies in Asia and Europe, DOD Biotech PCL will undoubtedly remain an important player in the global healthcare market in the future. DOD Biotech PCL ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering DOD Biotech PCL's P/E Ratio

The Price to Earnings (P/E) Ratio of DOD Biotech PCL is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing DOD Biotech PCL's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of DOD Biotech PCL is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in DOD Biotech PCL’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about DOD Biotech PCL Stock

What is the price-to-earnings ratio of DOD Biotech PCL?

The price-earnings ratio of DOD Biotech PCL is currently 263.23.

How has the price-earnings ratio of DOD Biotech PCL changed compared to last year?

The price-to-earnings ratio of DOD Biotech PCL has increased by -3,882.04% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of DOD Biotech PCL high compared to other companies?

Yes, the price-to-earnings ratio of DOD Biotech PCL is high compared to other companies.

How does an increase in the price-earnings ratio of DOD Biotech PCL affect the company?

An increase in the price-earnings ratio of DOD Biotech PCL would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of DOD Biotech PCL affect the company?

A decrease in the price-earnings ratio of DOD Biotech PCL would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of DOD Biotech PCL?

Some factors that influence the price-earnings ratio of DOD Biotech PCL are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does DOD Biotech PCL pay?

Over the past 12 months, DOD Biotech PCL paid a dividend of 0.05 THB . This corresponds to a dividend yield of about 2.27 %. For the coming 12 months, DOD Biotech PCL is expected to pay a dividend of 0 THB.

What is the dividend yield of DOD Biotech PCL?

The current dividend yield of DOD Biotech PCL is 2.27 %.

When does DOD Biotech PCL pay dividends?

DOD Biotech PCL pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of DOD Biotech PCL?

DOD Biotech PCL paid dividends every year for the past 0 years.

What is the dividend of DOD Biotech PCL?

For the upcoming 12 months, dividends amounting to 0 THB are expected. This corresponds to a dividend yield of 0 %.

In which sector is DOD Biotech PCL located?

DOD Biotech PCL is assigned to the 'Non-cyclical consumption' sector.

Wann musste ich die Aktien von DOD Biotech PCL kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of DOD Biotech PCL from 5/20/2020 amounting to 0.05 THB, you needed to have the stock in your portfolio before the ex-date on 3/13/2020.

When did DOD Biotech PCL pay the last dividend?

The last dividend was paid out on 5/20/2020.

What was the dividend of DOD Biotech PCL in the year 2023?

In the year 2023, DOD Biotech PCL distributed 0 THB as dividends.

In which currency does DOD Biotech PCL pay out the dividend?

The dividends of DOD Biotech PCL are distributed in THB.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von DOD Biotech PCL

Our stock analysis for DOD Biotech PCL Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of DOD Biotech PCL Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.